Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study
International Journal of Radiation Oncology*Biology*Physics · 2026
DOI: 10.1016/j.ijrobp.2025.01.014 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Ragu Ratnakumaran und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden NHS Foundation Trust, London, United Kingdom; Radiotherapy and Imaging Division, Institute of Cancer Research, London, United Kingd…. Hauptthemen laut MEDLINE: Radiosurgery, Prostatic Neoplasms, Organs at Risk, Radiotherapy Planning, Computer-Assisted. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, NIHR BRC, Biomedical Research Council.
Abstract (Originalsprache)
Purpose
In the PACE-B study, a nonrandomized comparison of toxicity outcomes between stereotactic body radiation therapy (SBRT) platforms revealed fewer urinary side effects with CyberKnife (CK) compared with conventional linac (CL) SBRT. This analysis compares baseline characteristics and planning dosimetry between the CK-SBRT and CL-SBRT cohorts in PACE-B, aiming to provide insight into possible reasons for differing toxicity outcomes between the platforms. Methods and Materials Dosimetric parameters for the surrogate urethra (SU), contoured urethra, bladder, bladder trigone (BT), and rectum were extracted from available computed tomography planning scans of PACE-B SBRT patients. The SU and BT were retrospectively delineated. Dose levels analyzed included maximum point dose (Dmax), D2, D50, and D95, where D(n) represents the dose (Gy) to (n)% of the structure. Baseline characteristics and planning dosimetry between the CK-SBRT and CL-SBRT cohorts were compared using Mann-Whitney U tests, t tests, and χ 2 tests.
Results
Of the 414 patients who received SBRT, 169 (41%) were treated with CK-SBRT and 245 (59%) with CL-SBRT, with dosimetric parameters available for 94% of patients (390/414). There was a nonstatistically significant trend toward more low-risk prostate cancer in the CK-SBRT cohort (12% vs 6% P = .02 [nonsignificant]). Margins were similar between platforms, except posteriorly, where CK-SBRT had smaller margins. CK-SBRT plans had significantly higher median SU Dmax (45.9 Gy vs 42.8 Gy, P < .0001), D2%, and D50% compared with CL-SBRT plans. Additionally, CK-SBRT plans had significantly higher median BT Dmax (43.4 Gy vs 41.6 Gy, P < .0001), D2%, and D95%, as well as higher median bladder Dmax, D50%, and D95%. CK-SBRT plans had lower median rectal D2% (35.5 Gy vs 36.0 Gy, P < .0001) but higher rectal D50% and D95%.
Conclusions
Although the CK-SBRT cohort showed lower urinary toxicity, the planned doses to urinary substructures were actually higher, likely due to heterogeneous dose planning. Factors like intrafraction tracking or other confounding variables may explain the differences in toxicity outcomes between the treatment platforms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Royal Marsden NHS Foundation Trust, London, United Kingdom; Radiotherapy and Imaging Division, Institute of Cancer Research, London, United Kingdom. Electronic address: ragu.ratnakumaran@icr.ac.uk.
- Radiotherapy and Imaging Division, Institute of Cancer Research, London, United Kingdom.
- The Royal Marsden NHS Foundation Trust, London, United Kingdom.
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
- Department of Medical Physics and Bioengineering, University College London, London, United Kingdom.
- Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Förderung
- Cancer Research UK
- NIHR BRC
- Biomedical Research Council
- Royal Marsden NHS Foundation Trust
Zitieren
APA
Ratnakumaran, R., Sasitharan, A., Khan, A., Mayet, H., Mohajer, J., Hinder, V., Brand, D. H., Fullarton, R., Loblaw, A., Hall, E., van As, N., & Tree, A. C. (2026). Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.01.014
Vancouver
Ratnakumaran R, Sasitharan A, Khan A, Mayet H, Mohajer J, Hinder V, et al. Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.01.014
BibTeX
@article{Ratnakumaran2026,
author = {Ratnakumaran, Ragu and Sasitharan, Archana and Khan, Asadullah and Mayet, Hira and Mohajer, Jonathan and Hinder, Victoria and Brand, Douglas H and Fullarton, Ryan and Loblaw, Andrew and Hall, Emma and van As, Nicholas and Tree, Alison C},
title = {Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2025.01.014}
}
EUVIMED